UCB SA

UCB: XBRU (BEL)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
%d^LOCK|>WLOCK|j@l?Bdp

UCB: Positive Long-Term Data Reinforces Confidence in Key Growth Drivers

During the second quarter, UCB presented additional long-term data for Bimzelx, published further evidence supporting recently launched rare-disease therapy Kygevvi, and released long-term data for Rystiggo and Zilbrysq. UCB reports half-yearly, with financial results due at the end of July.

Sponsor Center